Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.

  • Revenue in USD (TTM)49.00bn
  • Net income in USD11.11bn
  • Incorporated1901
  • Employees47.00k
  • Location
    Eli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LLY:NYQ since
announced
Transaction
value
Verve Therapeutics IncAnnounced17 Jun 202517 Jun 2025Announced-1.80%1.25bn
SiteOne Therapeutics IncAnnounced27 May 202527 May 2025Announced11.11%1.00bn
Scorpion Therapeutics IncAnnounced13 Jan 202513 Jan 2025Announced-0.86%2.50bn
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen Inc34.13bn5.93bn158.77bn28.00k26.9525.5813.764.6510.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Merck & Co Inc63.92bn17.43bn209.32bn75.00k12.134.349.473.276.876.8725.1919.210.57862.315.77852,293.3015.799.5220.4612.6477.0773.4727.3017.871.1623.900.418672.966.7410.404,589.5924.64-0.58856.66
AbbVie Inc57.37bn4.16bn339.94bn55.00k82.06239.3826.955.932.352.3532.390.8040.40253.834.701,043,036.002.955.444.067.0970.6968.897.3313.730.63597.800.9795134.963.7111.11-12.07-11.5812.037.69
Johnson & Johnson89.33bn21.81bn377.51bn138.10k17.444.8312.974.238.998.9936.8332.470.48862.355.77646,857.4011.938.6316.7811.7368.3468.7024.4118.291.03--0.400874.744.301.605.55-1.434.815.54
Eli Lilly And Co49.00bn11.11bn751.56bn47.00k64.4747.6758.1015.3412.3012.3054.2516.630.63921.164.921,042,621.0014.4912.6321.2619.3281.7078.2522.6621.081.0622.430.708555.3432.0015.08102.0817.9544.0815.05
Data as of Jul 11 2025. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

32.96%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202575.46m7.96%
PNC Bank, NA (Investment Management)as of 31 Mar 202551.07m5.39%
BlackRock Fund Advisorsas of 31 Mar 202541.47m4.38%
SSgA Funds Management, Inc.as of 31 Mar 202534.44m3.63%
Fidelity Management & Research Co. LLCas of 31 Mar 202524.54m2.59%
Geode Capital Management LLCas of 31 Mar 202518.53m1.96%
Capital Research & Management Co. (World Investors)as of 31 Mar 202518.38m1.94%
T. Rowe Price Associates, Inc. (IM)as of 31 Mar 202517.98m1.90%
Capital Research & Management Co. (Global Investors)as of 31 Mar 202515.75m1.66%
PRIMECAP Management Co.as of 31 Mar 202514.78m1.56%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.